FDA Accepts Supplement for POKONZA by Genus Lifesciences
The FDA has accepted a supplemental application for POKONZA, an electrolyte replacement therapy containing potassium chloride.
Therapeutic Area
Therapeutic area intelligence for Electrolyte Replacement with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.